SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Amir Hanna, Kim A Connelly, Robert G Josse, Roger S McIntyre, The non-glycemic effects of incretin therapies on cardiovascular outcomes, cognitive function and bone health, Expert Review of Endocrinology & Metabolism, 2015, 10, 1, 101

    CrossRef

  2. 2
    Alfonso Vidal Casariego, María Dolores Ballesteros Pomar, Isidoro Cano Rodríguez, El hueso en las enfermedades endocrinas y nutricionales, 2014,

    CrossRef

  3. 3
    C. Y. Shan, J. H. Yang, Y. Kong, X. Y. Wang, M. Y. Zheng, Y. G. Xu, Y. Wang, H. Z. Ren, B. C. Chang, L. M. Chen, Alteration of the intestinal barrier and GLP2 secretion in Berberine-treated type 2 diabetic rats, Journal of Endocrinology, 2013, 218, 3, 255

    CrossRef

  4. 4
    Charlotte Pinholt, Sebastian J. Kapp, Jens T. Bukrinsky, Susanne Hostrup, Sven Frokjaer, Willem Norde, Lene Jorgensen, Influence of acylation on the adsorption of GLP-2 to hydrophobic surfaces, International Journal of Pharmaceutics, 2013, 440, 1, 63

    CrossRef

  5. You have free access to this content5
    P. Janssen, A. Rotondo, F. Mulé, J. Tack, Review article: a comparison of glucagon-like peptides 1 and 2, Alimentary Pharmacology & Therapeutics, 2013, 37, 1
  6. 6
    Kelly A. Tappenden, Jeffrey Edelman, Bo Joelsson, Teduglutide Enhances Structural Adaptation of the Small Intestinal Mucosa in Patients With Short Bowel Syndrome, Journal of Clinical Gastroenterology, 2013, 47, 7, 602

    CrossRef

  7. 7
    Anna Svenningsson, Cilla Söderhäll, Sofia Persson, Fredrik Lundberg, Holger Luthman, Eddie Chung, Mark Gardiner, Ingrid Kockum, Agneta Nordenskjöld, Genome-wide linkage analysis in families with infantile hypertrophic pyloric stenosis indicates novel susceptibility loci, Journal of Human Genetics, 2012, 57, 2, 115

    CrossRef

  8. 8
    Xia Chen, Hong-Xian Zhao, Xiang-Sheng Fu, Chang-Ping Li, Xiao-Lin Zhong, Glucagonlike Peptide 2 Protects Intestinal Barrier in Severe Acute Pancreatitis Through Regulating Intestinal Epithelial Cell Proliferation and Apoptosis, Pancreas, 2012, 41, 7, 1080

    CrossRef

  9. 9
    Alessandra Rotondo, Antonella Amato, Sara Baldassano, Laura Lentini, Flavia Mulè, Gastric relaxation induced by glucagon-like peptide-2 in mice fed a high-fat diet or fasted, Peptides, 2011, 32, 8, 1587

    CrossRef

  10. 10
    L. Cinci, M. S. Faussone-Pellegrini, A. Rotondo, F. Mulè, M. G. Vannucchi, GLP-2 receptor expression in excitatory and inhibitory enteric neurons and its role in mouse duodenum contractility, Neurogastroenterology & Motility, 2011, 23, 9
  11. 11
    Keisuke Suzuki, Channa N. Jayasena, Stephen R. Bloom, The Gut Hormones in Appetite Regulation, Journal of Obesity, 2011, 2011, 1

    CrossRef

  12. 12
    Pamela J Hornby, Beverley A Moore, The therapeutic potential of targeting the glucagon-like peptide-2 receptor in gastrointestinal disease, Expert Opinion on Therapeutic Targets, 2011, 1

    CrossRef

  13. 13
    Jean-Francois Marier, Mohamad-Samer Mouksassi, Nathalie H. Gosselin, Martin Beliveau, Jane Cyran, John Wallens, Population Pharmacokinetics of Teduglutide Following Repeated Subcutanenous Administrations in Healthy Participants and in Patients With Short Bowel Syndrome and Crohn's Disease, The Journal of Clinical Pharmacology, 2010, 50, 1
  14. 14
    Monica H. Wojcik, Erinne Meenaghan, Elizabeth A. Lawson, Madhusmita Misra, Anne Klibanski, Karen K. Miller, Reduced amylin levels are associated with low bone mineral density in women with anorexia nervosa, Bone, 2010, 46, 3, 796

    CrossRef

  15. 15
    M S Mouksassi, J F Marier, J Cyran, A A Vinks, Clinical Trial Simulations in Pediatric Patients Using Realistic Covariates: Application to Teduglutide, a Glucagon-Like Peptide-2 Analog in Neonates and Infants With Short-Bowel Syndrome, Clinical Pharmacology & Therapeutics, 2009, 86, 6
  16. 16
    Raanan Shamir, Sanja Kolacek, Sibylle Koletzko, Irit Tavori, David Bader, Ita Litmanovitz, Orna Flidel-Rimon, Kyla Anna Marks, Igor Sukhotnik, Naim Shehadeh, Oral Insulin Supplementation in Paediatric Short Bowel Disease: A Pilot Observational Study, Journal of Pediatric Gastroenterology and Nutrition, 2009, 49, 1, 108

    CrossRef

  17. 17
    Alastair Forbes, Virtual Clinical Nutrition University: The compromised gut–intestinal failure. Challenges in treating intestinal failure and short bowel syndrome, e-SPEN, the European e-Journal of Clinical Nutrition and Metabolism, 2009, 4, 3, e108

    CrossRef

  18. 18
    Laurent Peyrin-Biroulet, Pierre Desreumaux, William J Sandborn, Jean-Frédéric Colombel, Crohn's disease: beyond antagonists of tumour necrosis factor, The Lancet, 2008, 372, 9632, 67

    CrossRef

  19. 19
    Jean-Francois Marier, Martin Beliveau, Mohamad-Samer Mouksassi, Paula Shaw, Jane Cyran, Jothi Kesavan, John Wallens, Hamim Zahir, David Wells, John Caminis, Pharmacokinetics, Safety, and Tolerability of Teduglutide, a Glucagon-Like Peptide-2 (GLP-2) Analog, Following Multiple Ascending Subcutaneous Administrations in Healthy Subjects, The Journal of Clinical Pharmacology, 2008, 48, 11
  20. 20
    Houssam E Mardini, Willem JS de Villiers, Teduglutide in intestinal adaptation and repair: light at the end of the tunnel, Expert Opinion on Investigational Drugs, 2008, 17, 6, 945

    CrossRef

  21. 21
    René Fiasse, Olivier Dewit, Novel therapies based on enhancement of gut innate immunity in inflammatory bowel disease, Expert Opinion on Therapeutic Patents, 2007, 17, 12, 1423

    CrossRef

  22. 22
    J. de Heer, J. Pedersen, C. Ørskov, J. J. Holst, The alpha cell expresses glucagon-like peptide-2 receptors and glucagon-like peptide-2 stimulates glucagon secretion from the rat pancreas, Diabetologia, 2007, 50, 10, 2135

    CrossRef